Image Credit: infowars 
Pfizer is forecasting $54 billion in Covid-related sales in 2022.
But the bad news on the horizon is quietly being discussed.
The evidence lies in Pfizer’s several redline changes in their Q4 earnings releases.
According to Rubicon Capital’s Kelly Brown, the changes center around disclosures of unfavorable safety data.
Stating that in Q4 they added: “or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection.”
